Evidence map›Paper›PMID 29111960›Full record

Trial reportInternational journal of stroke : official journal of the International Stroke Society2018

The aspirin in reducing events in the elderly trial: Statistical analysis plan.

Rory Wolfe, Anne M Murray, Robyn L Woods, Brenda Kirpach, David Gilbertson, Raj C Shah, Mark R Nelson, Christopher M Reid, Michael E Ernst, Jessica Lockery and 3 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of stroke : official journal of the International Stroke Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01038583 (Aspirin in Reducing Events in the Elderly), which is not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01038583 unknown statusnot on this map

Aspirin in Reducing Events in the Elderly

TypeobservationalSponsorHennepin Healthcare Research InstituteRan2010 to 2024Enrolled19,114ConditionsFunctional Disability, Dementia, Heart Disease, StrokeArms100 mg enteric-coated aspirin, Placebo
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.The New England journal of medicine · 2018
    Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 2 countries.

Rory Wolfe1 161667 School of Public Health and Preventive Medicine, Monash University , Melbourne, Australia.
Anne M Murray2 Hennepin County Medical Center, Berman Center for Outcomes and Clinical Research, 20298 Minneapolis Medical Research Foundation , Minneapolis, MN, USA.
Robyn L Woods1 161667 School of Public Health and Preventive Medicine, Monash University , Melbourne, Australia.
Brenda Kirpach2 Hennepin County Medical Center, Berman Center for Outcomes and Clinical Research, 20298 Minneapolis Medical Research Foundation , Minneapolis, MN, USA.
David Gilbertson4 20298 Minneapolis Medical Research Foundation , Chronic Disease Research Group, Minneapolis, MN, USA.
Raj C Shah5 Department of Family Medicine and Rush Alzheimer's Disease Center, 2468 Rush University Medical Center , Chicago, IL, USA.
Mark R Nelson6 Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Christopher M Reid1 161667 School of Public Health and Preventive Medicine, Monash University , Melbourne, Australia.
Michael E Ernst8 Department of Pharmacy Practice and Science, College of Pharmacy and Department of Family Medicine, Carver College of Medicine, 4083 University of Iowa , Iowa City, IA, USA.
Jessica Lockery1 161667 School of Public Health and Preventive Medicine, Monash University , Melbourne, Australia.ORCID 0000-0001-6664-1239
Geoffrey A Donnan9 University of Melbourne, Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Jeff Williamson10 Department of Internal Medicine, 12279 Wake Forest University School of Medicine , Winston-Salem, NC, USA.
John J McNeil1 161667 School of Public Health and Preventive Medicine, Monash University , Melbourne, Australia.
Monash University · AUCurtin University · AUHennepin County Medical Center · USOrthopaedic Research Foundation · USRush University Medical Center · USThe University of Melbourne · AUUniversity of Iowa · USUniversity of Minnesota · USUniversity of Tasmania · AUWake Forest University · US

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
NIA NIH HHS U01 AG029824
6 · The paper itself

Abstract

Rationale Aspirin has positive and negative effects on a number of age-related chronic conditions and there is uncertainty regarding its role in primary prevention in people aged 70 years and over. Aims To assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy older participants. Design A double-blind, randomized, placebo-controlled primary prevention trial undertaken in Australia and the United States with careful adjudication of endpoints including stroke. Study outcome In Australia 16,703 individuals were recruited through general practices across five states and territories, and in the United States, 2411 participants were recruited through 34 clinical sites across the country. Follow-up of participants will finish at the end of 2017 with average follow-up exceeding 4.25 years per person. Discussion The statistical analysis plan for ASPREE, finalized after closure of recruitment but before the end of patient follow-up, outlines the primary analyses and a range of subgroup and sensitivity analyses. (International Standard Randomized Controlled Trial Number Register ISRCTN83772183 and clinicaltrials.gov Number NCT01038583).

Indexed as

AgedAged, 80 and overAspirinAustraliaCardiovascular DiseasesDouble-Blind MethodFemaleFibrinolytic AgentsHumansLongitudinal StudiesMalePrimary PreventionStrokeUnited StatesAspirinFibrinolytic AgentsAspirinclinical trialdisability free survivalintracerebral hemorrhageischemic strokeprotocolsstatistical analysis plan

Identifiers

PMID29111960
PMCPMC6380180
OpenAlexW2767842448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.